NCT06039553

Brief Summary

The goal of this observational study is to learn about the safety and effectiveness of pulmonary artery banding(PAB) therapy in pediatric heart failure(PHF) patients. The main questions it aims to answer are:

  • Can PAB therapy improve left ventricular(LV) function in PHF patients especially refractory PHF.
  • Can the complications caused by the PAB therapy be clinically acceptable? Participants underwent PAB therapy will be required to underwent echocardiography, electrocardiograms, complete blood counts, biochemical tests, and measurements of N-terminal pro-brain natriuretic peptide (NT-proBNP) follow-up before the initiation of PAB and at 1 month, 3 months, and 6 months after PAB surgery. Researchers will compare the LV function 6 months after PAB suergey and the preoperative ones to see if there is improvement.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
25

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jan 2022

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2022

Completed
1.7 years until next milestone

First Submitted

Initial submission to the registry

September 9, 2023

Completed
6 days until next milestone

First Posted

Study publicly available on registry

September 15, 2023

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2024

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2024

Completed
Last Updated

September 15, 2023

Status Verified

September 1, 2023

Enrollment Period

2.7 years

First QC Date

September 9, 2023

Last Update Submit

September 9, 2023

Conditions

Keywords

congenital heart diseasepulmonary artery banding

Outcome Measures

Primary Outcomes (1)

  • the recurrence rate of heart failure

    During follow-up visits, echocardiographic examination is conducted to measure the left ventricular function. If LVEF falls under 55%, it is recorded as a recurrence.

    after 6 months of PAB surgery

Secondary Outcomes (3)

  • NT-proBNP level

    after 6 months of PAB surgery

  • Incidence rate of drug adverse reactions

    after 6 months of PAB surgery

  • Readmission rate for heart failure

    after 6 months of PAB surgery

Study Arms (1)

Pulmonary Artery Banding Group

Patient in this group will undergo pulmonary artery banding surgery for congenital heart disease.

Procedure: pulmonary artery banding

Interventions

Patient in this group will undergo pulmonary artery banding surgery for congenital heart disease.

Pulmonary Artery Banding Group

Eligibility Criteria

AgeUp to 14 Years
Sexall
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

paitent younger than 14 years of age with heart failure

You may qualify if:

  • patients younger than 14 years of age
  • congenital heart failure (LVEF\<55%, or LVFS\<25%)

You may not qualify if:

  • single ventricle
  • congenital heart disease without anatomical correction
  • Patients with heart failure requiring ventricular assist or cardiac synchronization therapy
  • Patients with severe pulmonary hypertension (pulmonary arterial pressure \>6 Wood·U)
  • Patients with severe liver and kidney failure
  • Patients who are allergic to related medications
  • Patients with symptomatic hypotension who cannot tolerate related drugs
  • Refuse to sign the informed consent or refuse to participate in this experiment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fuwai hospital

Beijing, Beijing Municipality, 100037, China

RECRUITING

MeSH Terms

Conditions

Heart Defects, Congenital

Condition Hierarchy (Ancestors)

Cardiovascular AbnormalitiesCardiovascular DiseasesHeart DiseasesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Officials

  • Shoujun Li, MD

    Chinese Academy of Medical Sciences, Fuwai Hospital

    STUDY CHAIR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
6 Months
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director of Congenital Heart Surgery Center

Study Record Dates

First Submitted

September 9, 2023

First Posted

September 15, 2023

Study Start

January 1, 2022

Primary Completion

September 1, 2024

Study Completion

December 31, 2024

Last Updated

September 15, 2023

Record last verified: 2023-09

Data Sharing

IPD Sharing
Will not share

Locations